Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study of IMR-687 in Subjects With Sickle Cell Disease

ClinicalTrials.gov ID: NCT04474314

Public ClinicalTrials.gov record NCT04474314. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects With Sickle Cell Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease

Study identification

NCT ID
NCT04474314
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Enrollment
115 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 12, 2020
Primary completion
Mar 1, 2022
Completion
May 3, 2022
Last update posted
May 14, 2025

2020 – 2022

United States locations

U.S. sites
14
U.S. states
12
U.S. cities
14
Facility City State ZIP Site status
University of Alabama at Birmingham School of Medicine - 1917 Clinic Birmingham Alabama 35233
Arkansas Primary Care Clinic Little Rock Arkansas 72204
University of California San Diego Moores Cancer Center La Jolla California 92093
Center For Inherited Blood Disorders Santa Ana California 92705
The Oncology Institute Long Beach Whittier California 90603
University of Connecticut Health Main Building Farmington Connecticut 06030
Children's Healthcare of Atlanta Atlanta Georgia 30342
The University of Illinois at Chicago College of Medicine Chicago Illinois 60612-4333
Johns Hopkins Hospital Baltimore Maryland 21287
Children's Hospital of Michigan Detroit Michigan 48201
Newark Beth Israel Medical Center Newark New Jersey 07112
Weill Cornell Medicine - Center for Blood Disorders New York New York 10021
Baylor Scott & White Medical Center-Temple Temple Texas 76508
Virginia Commonwealth University Health - Ambulatory Care Center Richmond Virginia 23219

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04474314, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 14, 2025 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04474314 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →